news aktuell GmbH

The Quality Group grows H1 revenue by more than 40% to over €850 million

21.7.2026 10:04:58 CEST | news aktuell GmbH | Press Release

Share
  • H1 2026 revenue reached €850 million – up more than 40% versus H1 2025
  • Demand continues to grow as more consumers seek better nutrition, health and performance solutions
  • Company growth is broad-based, reflecting successful execution of strategies across brands, product categories, channels, and markets
The Quality Group Headquarters, Elmshorn
The Quality Group Headquarters, Elmshorn

Elmshorn, 21 July 2026 – The Quality Group (TQG), the German-based global trendsetter in „better-for-you“-nutrition, closed the first half of 2026 with strong momentum, growing organic revenue more than 40% to €850 million – following the milestone of surpassing €1 billion in annual revenue in 2025. The performance reflects strong consumer demand and the strength of TQG's differentiated business model.

TQG has driven growth across the four brands ESN, More Nutrition, RAW Nutrition and BUM Energy through a consistent strategy: sustained focus on product quality, expansion into adjacent categories, an expanding omnichannel distribution footprint, and a growing international presence.

Heikki Takala, CEO of The Quality Group: “Consumers are choosing better nutritional alternatives to support their well-being and performance. TQG’s strategy is to bring these better alternatives to more people, in more usage occasions, in more channels, and more countries. We are executing the strategy successfully, backed by our community, innovation, uncompromising quality, strong operations, and ambitious teams. As a result, we are becoming a true growth compounder, growing sustainably and delivering value, with the ambition to become a global industry leader.”    

The global market, especially the protein segment, has witnessed significant raw material volatility and inflationary pressures. TQG's integrated platform and in-house production have enabled the company to maintain the strong momentum and operational agility.

For the second half of 2026, TQG is preparing exciting product launches and new product concepts, while continuing to expand its footprint across channels and markets. To support the long-term growth, the company continues to invest in its northern German operations facilities as well as its global capabilities.

Contacts

Images

The Quality Group Headquarters, Elmshorn
The Quality Group Headquarters, Elmshorn
Download

About The Quality Group

The Quality Group (TQG) is a leading better-for-you nutrition player in Europe and recently expanded into North America. TQG develops science-backed functional nutrition through its brands ESN, More Nutrition, RAW Nutrition and BUM Energy. The company combines category-leading brands with an integrated platform across product development, manufacturing, technology and omnichannel distribution. Headquartered in Elmshorn, Germany, the company employs more than 1,600 people and generated more than €1 billion in revenue in 2025. The company is backed by CVC Capital Partners.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Polpharma Strengthens Its Position in Central and Eastern Europe – Biofarm, the Leader of the Romanian Market, Joins the Group21.7.2026 11:00:00 CEST | Press Release

Warsaw, 21.07.2026 - Polpharma Group has completed the acquisition of the Romanian pharmaceutical company Biofarm. The transaction is a clear step in the execution of the Group’s growth strategy and strengthens its position in Central and Eastern Europe. With Biofarm joining the Group, Polpharma is expanding the scale of its operations, reinforcing its presence in key regional markets, and creating new opportunities to improve patients’ access to trusted medicines across the region and beyond.

Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich16.7.2026 10:32:18 CEST | Press Release

Aachen, Germany, 16 July 2026 – Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic acid therapeutics into innovative treatments that can make a meaningful difference for patients. Joining the CNATM provides Grünenthal with a valuable platform to strengthen its oligonucleotide drug discovery capabilities and connect its growing internal expertise with one of Germany’s leading academic and biotech innovation ecosystems. Over the last few years, Grünenthal has built strategic in-house capabilities to advance oligonucleotide modalities, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA), as potential therapeutic approaches for pain and related neurological indications. One of Grünenthal’s key objectives for the collaboration

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye